fda statement bpc-157 not approved fda.gov An advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8-6 votes (with An FDA panel will consider
An FDA panel will consider whether to allow compounding pharmacies to manufacture certain peptides. Here's what to know about their safety and efficacy. Undercutting HHS Secretary Robert F. Kennedy Jr.'s recent push to expand access to peptides, FDA career scientists determined there isn't adequate evidence to support any of the ones under consideration for production BPC 157 PASSED! Gabriel Alizaidy, MD, MS I also agree with you, the FDA's data pitch was very disappointing For the compounding industry, this is a positive vote. It does not immediately make A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring!
Pay in 4 interest-free payments of $6.62 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16